Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

51 results about "Prognostic factor" patented technology

Prognostic factor. Any feature of a disease or of a patient's presentation that suggests that he or she will be affected for better or worse by an illness. See also: factor.

Lung cancer lifetime prediction system based on prognosis factor multi-data fusion

The invention discloses a lung cancer lifetime prediction system based on prognosis factor multi-data fusion, and belongs to the technical field of lung cancer prognosis prediction, and the system comprises a multi-source data collection module which is used for collecting prognosis multi-source data of a patient; the multi-source data processing module is used for carrying out preprocessing and feature extraction on the prognosis multi-source data of the patient; the multi-source data fusion module is used for carrying out cross-modal alignment and fine-grained fusion on the extracted multi-modal feature vectors, and capturing a dependency relationship between modals based on a hierarchical attention mechanism to form patient prognosis fusion data; and the survival analysis and prediction module is used for analyzing the prognosis fusion data of the patient according to the lung cancer lifetime prediction model, automatically predicting the lifetime of the patient and displaying the lifetime in a visual form. The problems that existing lung cancer lifetime prediction is low in accuracy and cannot provide support for personalized treatment are solved. The lung cancer lifetime prediction accuracy can be improved, and support can be provided for personalized treatment.
Owner:中国人民解放军总医院第八医学中心

Preoperative risk stratification system based on liver resection after transformation treatment

The invention discloses a preoperative risk stratification system based on hepatic resection after transformation treatment in the technical field of biomedicine, and the system comprises a sample module which is used for selecting a proper hepatocellular carcinoma patient as a sample, distributing the patient sample to a training queue and an internal verification queue, and building an external verification queue; the treatment module is used for providing a treatment strategy for the patient based on whether liver resection is performed or not after conversion treatment; the tracking module is used for carrying out regular follow-up visit on the patient subjected to the liver resection or not subjected to the liver resection after the conversion treatment; and the data analysis module is used for determining prediction factors related to recurrence-free survival in the training queue by adopting a minimum absolute contraction and selection operator regression analysis method, further analyzing and screening out independent prognosis factors through multivariable Cox regression, and constructing a column graph based on the factors to predict the postoperative recurrence rate. Through verification of the internal and external verification queues, the method can effectively guide and select a patient who is most likely to benefit from the liver resection operation after transformation treatment.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Methods of determining whether a subject suffering from lupus nephritis (LN) will achieve a response with an induction therapy

Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, according to immune deposits and to the type of glomerular cell injury. Proliferative lesions represent the most severe form of lupus nephritis (LN) and often lead to kidney failure and death. Mucosal-associated invariant T (MAIT) are a subset of innate-like T cells that recognize microbial-derived ligands from the riboflavin synthesis pathway. Now the inventors analyzed the phenotype and function of peripheral blood MAIT cells by flow cytometry in 26 patients with LN and in a control group of 16 healthy volunteers. The inventors found that MAIT cell frequencies are markedly reduced in blood of LN patients. More particularly, among LN patients, baseline MAIT cell frequency, Ki-67 expression evaluating proliferative activity and granzyme B production measuring cytotoxicity represent promising prognostic factors of renal response one year after induction therapy. In conclusion, the inventors showed that baseline frequency and cytotoxic profile of MAIT cells may represent a promising prognostic factor of renal remission one year after induction therapy.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

MicroRNA-198 as a tumor suppressor in ovarian cancer

A novel network of tumorigenic prognostic factors is identified that plays a critical role in advanced pancreatic cancer (PC) pathogenesis. This interactome is interconnected through a central tumor suppressive microRNA, miR-198, which is able to both directly and indirectly modulate expression of the various members of this network to alter the molecular makeup of pancreatic tumors, with important clinical implications. When this tumor signature network is intact, miR-198 expression is reduced and patient survival is dismal; patients with higher miR-198 present an altered tumor signature network, better prognosis and increased survival. Further, according to the present disclosure, MiR-198 replacement reverses tumorigenicity in vitro and in vivo. As such, an embodiment of the disclosure is a method of treating cancer in an individual, comprising the step of increasing the level of active microRNA-198 molecules in the pancreatic cancer tumor cells of the individual by an amount sufficient to cause an improvement in the pancreatic cancer in the individual.
Owner:BAYLOR COLLEGE OF MEDICINE

Creating a tumor bud ground truth of H AND E stained slides and automated identification of tumor buds using an H AND E stained slides

ActiveUS12784207B2StainingOncology
Tumor budding (TB) is defined as a cluster of one to four tumor cells at the tumor invasive front. Though promising as a prognostic factor for colorectal cancer, its routine clinical use is hampered by high inter-and intra-observer disagreement on routine H&E staining. Therefore, automated methods are provided that minimize the inter-and intra-observer disagreement for tumor bud detection on images of H&E-stained tissue sections.
Owner:WAKE FOREST UNIVERSITY HEALTH SCIENCES INC +1

Application of Hsa-miR-24-3p in construction of pancreatic ductal adenocarcinoma postoperative total lifetime prediction model

PendingCN120126568AHealth-index calculationMicrobiological testing/measurementPancreas Ductal AdenocarcinomaAdenocarcinoma
The invention discloses an application of Hsa-miR-24-3p in construction of a pancreatic ductal adenocarcinoma postoperative total lifetime prediction model. According to the invention, the expression of Hsa-miR-24-3p in preoperative serum of a PDAC patient is analyzed, and the total lifetime of a patient with increased level of Hsa-miR-24-3p (miR-24) is obviously reduced (Plt; 0.0001) of the method for manufacturing the same; multi-factor analysis shows that miR-24 is a prognosis factor independent of the age, gender and clinical pathological characteristics of a patient, and the prediction efficiency of miR-24 is remarkable; the area under the ROC curve reaches 0.82, which is superior to the area under the CA19-9 (0.61), the area under the CA125 (0.59), the area under the CA50 (0.51) and the area under the CEA (0.56); when the miR-24 and the TNM are staging, and the CA19-9 and the CA125 are integrated into the column diagram model, the prognosis prediction accuracy is further improved.
Owner:KANTE (SHENZHEN) BIOTECHNOLOGIES INC

Risk stratification model of HIV (Human Immunodeficiency Virus) combined hepatocellular carcinoma and construction method thereof

The invention discloses an HIV (human immunodeficiency virus) combined hepatocellular carcinoma risk stratification model and a construction method thereof, the construction method comprises the following steps: obtaining clinical data of an HIC-HCC patient, the clinical data comprising demographic information, clinical feature information and treatment and outcome information; taking the total lifetime of the patient as an outcome, performing single-factor analysis on the clinical data, and screening out a plurality of risk factors influencing the total lifetime of the patient; performing multi-factor analysis on the plurality of risk factors to obtain independent prognosis factors of the total lifetime of the patient; the independent prognosis factors comprise organ fatigue and multiple tumors; and establishing a risk layering model based on the independent prognosis factors.
Owner:GUANGZHOU EIGHTH PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV

Application of GLUT5 as colorectal cancer biomarker in development of in-vitro detection kit, prognosis model and inhibitor

The invention belongs to the technical field of biological medicine, and particularly relates to application of GLUT5 serving as a colorectal cancer biomarker in development of an in-vitro detection kit, a prognosis model and an inhibitor. The GLUT5 is highly expressed in colorectal cancer tumor-related fibroblasts (CAFs), the expression level of the GLUT5 is remarkably related to poor prognosis of a patient, and the GLUT5 can be used as a molecular basis for auxiliary diagnosis and an independent prognosis factor. In mechanism, the GLUT5 promotes tumor progression by mediating fructose metabolism reprogramming of the CAFs. A full-chain solution from early diagnosis and precise prognosis to targeted therapy is provided for colorectal cancer, and the clinical transformation value is remarkable.
Owner:TIANJIN TUMOR HOSPITAL

Application of lactic acid modified gene ENO1 inhibitor in preparation of medicine for treating nasopharynx cancer

The invention discloses application of a lactic acid modified gene ENO1 inhibitor in preparation of a medicine for treating nasopharynx cancer, and relates to the technical field of biological medicines. A head and neck squamous cell carcinoma prognosis model containing seven lactylation related genes is constructed by analyzing a TCGA database, the model can effectively distinguish patient risks, the total lifetime of a high-risk group is remarkably shortened, and a risk score is an independent prognosis factor; the functions of the key gene ENO1 are deeply studied through in-vitro experiments, and experimental results show that silencing of the ENO1 gene in nasopharynx cancer 5-8F cells causes up-regulation of cell pan-lactylation level, up-regulation of MMP2 expression and down-regulation of E-cadherin expression, and migration and invasion ability of tumor cells is significantly enhanced. The prognosis model provided by the invention has an important clinical prediction value, inhibition of ENO1 can promote tumor progression through abnormal lactylation, and a new thought is provided for taking ENO1 as a treatment target.
Owner:THE PEOPLES HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION

Prognosis layering model of preliminarily diagnosed patient with extramedullary lesion as well as construction method and application of prognosis layering model

The invention relates to the field of biological detection, in particular to a prognosis layering model of a preliminarily diagnosed patient with extramedullary lesion as well as a construction method and application of the prognosis layering model. The prognosis layering model comprises an independent prognosis factor index, a prognosis model expression, a layering group and a prognosis state corresponding to the layering group. Independent prognosis factor indexes are bone marrow Ki67 level, eGFR and blood mononuclear cell count. According to the method, the prognosis layering model is constructed by adopting common experimental actual indexes, so that the method has the advantages of accuracy and universal applicability.
Owner:JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)

Gender-specific advanced young non-small cell lung cancer prognosis model construction method

The invention relates to the technical field of medical prognosis evaluation, in particular to a sex-specific advanced young non-small cell lung cancer prognosis model construction method, which collects clinical data of young metastatic non-small cell lung cancer patients, including sex, age, body mass index, D-2 polymer level, gene mutation state, metastasis site, tumor marker and hematology index. Data are divided into male and female queues, male specific prognostic factors (body mass index, gene mutation state and liver metastasis state) and female specific prognostic factors (D-2 polymer level and gene mutation state) are identified through Cox proportional risk regression analysis, and male and female column map prognostic models are respectively constructed based on the factors. All prognosis factors are converted into risk scores, the corresponding relation between the total score and the survival probability is established, finally, the model can output individualized survival probability prediction results of patients of different genders, and important reference is provided for clinical treatment and prognosis evaluation.
Owner:THE FOURTH HOSPITAL OF HEBEI MEDICAL UNIVERSITY (HEBEI CANCER HOSPITAL)

Deep learning-based pneumoconiosis prognosis multi-outcome competition risk prediction method

The invention discloses a pneumoconiosis prognosis multi-outcome competition risk prediction method based on deep learning, and the method comprises the following steps: (1) obtaining basic data, and constructing a database, the basic data including social state, life health habits, dust catching factors, gene infectivity, disease conditions, inspection indexes, and outcomes; (2) processing the basic data: processing abnormal values in the basic data by using an interpolation method, and creating a data set for the basic data by using a synthetic minority class oversampling technology; and (3) constructing a pneumoconiosis outcome prognosis prediction model by using the data set constructed in the step (2) through a DNN neural network, and training the pneumoconiosis outcome prognosis prediction model to obtain a final prediction model. According to the method, the pneumoconiosis is effectively prevented, and the loss of labor capacity and economic benefits of pneumoconiosis patients is reduced by managing bad prognosis factors of the pneumoconiosis.
Owner:SICHUAN UNIV

PAML SCT risk stratification prognosis model and construction method thereof

The invention discloses a pAML SCT risk stratification prognosis model and a construction method thereof, and belongs to the field of children acute myelogenous leukemia stem cell transplantation risk prognosis research. Clinical data of a pAML patient are collected and analyzed by adopting a statistical method, a risk stratification model is established according to prognosis factors including combination of diagnosis age, KMT2A-r state and MRD1 state, and through verification, the pAML SCT risk can be effectively predicted by adopting the total lifetime prognosis model and the event-free lifetime prognosis model; the risk group of the patient can be determined according to the diagnosis age, the KMT2A-r state and the MRD1 state, so that a clinician is assisted in judging clinical development and disease outcome of the patient, precise layered treatment is realized, and the doctor can guide and / or identify candidates suitable for stem cell transplantation and formulate a treatment scheme.
Owner:CHILDRENS HOSPITAL OF CHONGQING MEDICAL UNIV

A postoperative risk early warning method and system based on machine learning

The application relates to the technical field of postoperative early warning, and particularly discloses a postoperative risk early warning method and system based on machine learning, which belongs to the technical field of postoperative early warning, and the method comprises the following steps: acquiring historical patient data of a plurality of patients who have undergone a to-be-early-warned operation, determining an adverse prognosis set of the to-be-early-warned operation and adverse data of each adverse prognosis in the adverse prognosis set; determining an influence factor vector of each adverse prognosis in the adverse prognosis set and an independent prognosis factor set; determining a plurality of preset non-independent factor sets of each adverse prognosis in the adverse prognosis set; determining a non-independent prognosis factor set of each adverse prognosis in the adverse prognosis set; and realizing postoperative risk early warning. The postoperative risk early warning method can comprehensively cover the postoperative risk influence dimension, accurately capture data correlation, realize intelligent transformation from data to risk prediction, provide more accurate and comprehensive postoperative risk early warning for the clinic, and improve the scientificity, accuracy and reliability of postoperative risk early warning.
Owner:马鞍山市人民医院

Colorectal cancer ihc staining map immune grading method, system, and storage medium

The application discloses a colorectal cancer IHC staining image tumor infiltration front immune grading method, system and storage medium, and the method comprises the following steps: acquiring a colorectal cancer IHC staining image; classifying the staining image by using a trained convolutional neural network classifier to obtain nine types of tissues, namely tumor epithelium, tumor interstitium, tumor necrosis, mucus, muscle, normal gland, lymph aggregation, fat and background; merging the nine types of tissue categories into five categories to automatically determine a tumor infiltration front and a tumor center area; performing cell segmentation and counting on the above-mentioned areas to obtain CD3 and CD8 positive cell densities, and then performing immune grading; the application quantifies the CD3 and CD8 positive cell densities in the tumor infiltration front and the tumor center area by automatically determining the tumor infiltration front and the tumor center area, evaluates the CD3 and CD8 positive cell densities in the tumor infiltration front as a prognostic factor, and thus assists pathologists in diagnosing and treating colorectal cancer patients.
Owner:GUANGDONG GENERAL HOSPITAL

A method and system for assessing the risk of gout flare based on neutrophil to lymphocyte ratio

The application provides a gout recurrence risk assessment method and system based on a neutrophil-to-lymphocyte ratio, comprising: data acquisition, data preprocessing, and generating gout recurrence risk assessment sample data through data standardization processing; establishing a joint model of a Cox proportional hazards regression model and a competing risk model to evaluate the correlation between the neutrophil-to-lymphocyte ratio (NLR) and gout recurrence; adding NLR as a characteristic variable of a prognosis factor of gout recurrence risk to a baseline model to construct multiple gout recurrence risk candidate prediction models; screening to obtain a target gout recurrence risk assessment model; generating an evaluation result; and visual display. The method can effectively handle the problems of incomplete and skewed distribution of clinical data, improve the quality and stability of the data, improve the accuracy of evaluation and prediction by screening out an effective target gout recurrence risk assessment model, and provide reliable auxiliary decision support for clinicians.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Gout recurrence risk assessment method and system based on ratio of neutrophil to lymphocyte

The invention provides a gout recurrence risk assessment method and system based on the ratio of neutrophil to lymphocyte. The method comprises the steps of data collection, data preprocessing and generation of gout recurrence risk assessment sample data through data standardization processing; establishing a combined model of a Cox proportional risk regression model and a competitive risk model, and evaluating the correlation between the ratio NLR of neutrophil to lymphocyte and gout recurrence; taking the NLR as a characteristic variable of a gout recurrence risk prognosis factor, adding the NLR into the baseline model, and constructing a plurality of gout recurrence risk candidate prediction models; screening to obtain a target gout recurrence risk assessment model; generating an evaluation result; and performing visual display. According to the method, the problems of incomplete and skewed distribution of clinical data can be effectively solved, the quality and stability of the data are improved, the accuracy of evaluation and prediction is improved by screening out the effective target gout recurrence risk evaluation model, and reliable auxiliary decision support is provided for clinicians.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Application of FASN inhibitor in preparation of medicine for treating KAT2B low-expression renal cell carcinoma

The invention relates to the technical field of biomedicine, and discloses application of an FASN inhibitor in preparation of a medicine for treating KAT2B low-expression renal cell carcinoma. According to the invention, development of a lipid metabolism related biomarker is realized, it is determined that the biomarker is an independent prognosis factor KAT2B in RCC, high methylation of a KAT2B promoter region causes down-regulation of expression of the biomarker, then lipid generation and development of the RCC are enhanced, a mechanism of KAT2B / HDAC5 / LSD1 / FASN axis for inhibiting the lipid generation and development of the RCC in vivo is proposed for the first time, KAT2B is acetylated at a K726 site of HDAC5, and KAT2B and LSD1 / FASN are used for inhibiting the lipid generation and development of the RCC. The FASN inhibitor can be used for inhibiting cancer cell targeting and promoting extranuclear transport of the FASN inhibitor, so that the FASN inhibitor and LSD1 cannot form a compound in a cell nucleus, the histone methylation level is increased, FASN expression is reduced, and a new thought is provided for research and development of products for inhibiting cancer cell targeting through the FASN inhibitor.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Kit for method for predicting or assessing prognosis of glioma patients

The invention provides a kit for a method for predicting or evaluating the prognosis of a glioma patient. In combination with immune-related genes, a group of characteristic genes capable of stably predicting the prognosis of the diffuse glioma is found; by adopting the system disclosed by the invention, the prognosis of the diffuse glioma can be well predicted; single-factor and multi-factor Cox proportional risk regression analysis is further carried out, and it is proved that the immune risk score can be really used as an independent prognosis factor of the diffuse glioma.
Owner:GUANGDONG ZHONGKE QINGZI MEDICAL TECH CO LTD

Construction method of prostatic cancer patient prognosis risk prediction model

The invention relates to the technical field of medical artificial intelligence and prognosis prediction, and discloses a construction method of a prognosis risk prediction model for prostate cancer patients. According to the method, a diagnosis and treatment state transition topology is formed by creating a hierarchical knowledge network and mining diagnosis and treatment path time sequence dependence, and a whole disease course time sequence data segment of a patient is depicted according to the topology. Synchronously operating a feature selection cycle of simulated annealing optimization, and performing dynamic interactive training with a depth prediction architecture containing a multi-scale time sequence attention mechanism to realize online adaptive screening of feature subsets; and constructing a feature influence propagation graph according to a feature selection process, identifying a key feature cluster, and performing guided correction on the attention weight of the model according to the key feature cluster. And integrating the components to form a prediction model, and establishing an online self-adaptive fine tuning loop. According to the method, feature combination can be effectively optimized, the focusing capability and prediction robustness of the model for key prognosis factors are improved, and increment adjustment according to new data is supported.
Owner:DEHUA COUNTY HOSPITAL

Methods and compositions for treating triple negative breast cancer (TNBC)

PendingUS20240426823A1Disease diagnosisAntineoplastic agentsCancer cellShort survival
Inventors analyzed the prognostic value of tumor and stromal-derived SPARC in a large series that included 148 non-metastatic TNBC patients with a long follow-up by immunohistochemistry. They show that SPARC expression was detected in cancer cells (42.4%), cancer-associated fibroblasts (CATs) (88.1%). TAMs (77.1%), endothelial cells (75.2%) and TILs (9.8%). Recurrence-free survival (RFS) was significantly lower for patients with a positive expression of SPARC in CATs (SPARC+CATs) with a median follow-up of 5.4 years. SPARC expression in CATs was found to be an independent prognostic factor in multivariate analysis. Accordingly, the present invention relates to a method for predicting the survival time of a subject suffering from triple-negative breast cancer (TNBC) comprising determining the expression level of Secreted Protein Acidic and Rich in Cysteine (SPARC) in cancer-associated fibroblasts (CATs) in a biological sample obtained from the subject wherein said positive expression of SPARC in CATs (SPARC+CAFs) correlates with a short survival time of the subject.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Rectum cancer prognosis model construction method and system based on deep learning

The invention relates to the technical field of biomedicine, and discloses a rectal cancer prognosis model construction method based on deep learning, and the method comprises the following steps: identifying disease characteristics of a rectal cancer patient, and defining prognosis requirements of the rectal cancer patient according to a baseline standard of the disease characteristics; determining focus types and iconography characteristics of the rectal cancer patients, and analyzing key prognosis indexes of the rectal cancer patients in combination with the focus types and the iconography characteristics; analyzing prognosis influence factors of the rectal cancer patient, and extracting characteristic data of the medical data; key prognosis features of the rectal cancer prognosis features are extracted, and derived features are determined; and setting a survival analysis result of the rectal cancer patient, and constructing a prognosis model of the rectal cancer patient in combination with the key prognosis characteristics, the derived characteristics and the survival analysis result. The use efficiency and generalization ability of the prognosis model can be improved.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Non-small cell lung cancer immunotherapy prognosis risk assessment method, system and medium

The invention relates to the technical field of medical information, and discloses a non-small cell lung cancer immunotherapy prognosis risk assessment method and system and a medium, and the method comprises the steps: obtaining clinical data including clinical variables, progression-free lifetime (PFS) and total lifetime (OS); taking each clinical variable as a hierarchical index to divide patient subgroups, and screening out hierarchical indexes with significant differences; then, aiming at each subgroup divided by the screened hierarchical indexes, quantifying prognosis influence of other clinical variables on the corresponding subgroup by adopting a risk regression model; and finally, screening out determinants with prognosis values according to a quantification result, dividing the determinants into different prognosis recommendation levels, and constructing a risk assessment matrix. According to the method, through a two-stage screening strategy of firstly identifying the effective hierarchical indexes and then analyzing the prognosis factors, evaluation deviation caused by generalization of local effective factors or neglecting of global non-significant factors is avoided, so that the accuracy and clinical practicability of prognosis evaluation are remarkably improved.
Owner:CHIMEDICAL UNIVERSITY

Method for evaluating prognosis curative effect of drug treatment of liver cancer patient based on radiomics

The invention provides a method for evaluating a prognosis curative effect of drug treatment of a liver cancer patient based on radiomics, and belongs to the technical field of biomedical detection. According to the method, the body composition is evaluated through L3 level CT scanning, sarcopenia (Sarcopenia) is defined by skeletal muscle index (SMI), and muscle steatosis (Myosteatosis) is defined by skeletal muscle density (SMD). Progression-free lifetime (PFS) and overall lifetime (OS) are evaluated, and single-factor and multi-factor Cox regression analyses are performed to identify prognostic factors. Experimental results show that sarcopenia and muscle fatty degeneration are important predictive factors for poor prognosis of HCC patients receiving HAIC combined targeted therapy and immunotherapy, especially sarcopenia, and are independent risk factors of OS. Therefore, the body component detection method plays an important role in prognosis evaluation and treatment decision, and can be well used for prognosis curative effect evaluation of drug treatment of the liver cancer patient.
Owner:FUDAN UNIV SHANGHAI CANCER CENT

Postoperative risk early warning method and system based on machine learning

The invention relates to the technical field of postoperative early warning, particularly discloses a postoperative risk early warning method and system based on machine learning, and belongs to the technical field of postoperative early warning. Determining a bad prognosis set of the operation to be pre-warned and bad data of each bad prognosis in the bad prognosis set; determining an influence factor vector of each bad prognosis in the bad prognosis set and an independent prognosis factor set; determining a plurality of preset non-independent factor sets of each bad prognosis in the bad prognosis set; determining a non-independent prognosis factor set of each bad prognosis in the bad prognosis set; and post-operation risk early warning is realized. According to the method, the postoperative risk influence dimension can be comprehensively covered, data association can be accurately captured, intelligent conversion from data to risk prediction is realized, more accurate and comprehensive postoperative risk early warning is provided for clinic, and the scientificity, accuracy and reliability of postoperative risk early warning are improved.
Owner:马鞍山市人民医院

Risk stratification assessment model, device and construction method for runx1: :runx1t1 positive childhood acute myeloid leukemia

PendingCN122135964AMedical data miningHealth-index calculationClinical variablesChildhood Acute Myeloid Leukemia
This invention discloses a risk stratification assessment model, device, and construction method for RUNX1::RUNX1T1-positive children with acute myeloid leukemia. The construction method includes: acquiring sample clinical data; assessing the correlation between clinical predictors and overall survival (OS) and event-free survival (ORS); for continuous variables, determining the optimal risk cutoff value for predicting poor prognosis; converting the continuous variables into binary variables; performing univariate Cox proportional hazards regression analysis to screen for factors significantly associated with OS and ORS; and incorporating these factors into a multivariate Cox proportional hazards regression model to confirm independent prognostic factors. This invention systematically integrates the clinical variable MRD1 and the percentage of peripheral blood blasts at diagnosis as core predictors, constructing a model capable of accurately assessing ORS. + A prognostic model for pAML risk was developed and rigorously validated. This model demonstrated superior predictive performance, effectively and accurately identifying patients with a high actual risk of relapse and death from the traditionally low-risk patient population.
Owner:CHONGQING MATERNAL & CHILD HEALTH HOSPITAL (CHONGQING OBSTETRICS & GYNECOLOGY HOSPITAL CHONGQING INST OF GENETICS & REPRODUCTION)

Application of exosome lncOSLMT in the diagnosis and treatment of osteosarcoma lung metastases

This invention belongs to the field of biomedical technology and discloses the application of exosomal lncOSLMT in the diagnosis and treatment of osteosarcoma lung metastases. This invention discloses the application of reagents for detecting lncOSLMT in the preparation of products for risk diagnosis or prognostic assessment of osteosarcoma lung metastases. Through research, this invention found that lncOSLMT selectively accumulates in exosomes released by osteosarcoma cells with high metastatic potential. Its elevated expression is positively correlated with the incidence of lung metastasis and serves as an independent prognostic factor for poor prognosis in osteosarcoma patients. This invention elucidates the regulatory role of lncOSLMT in the pre-metastatic microenvironment of osteosarcoma lung metastases and its effect on lung metastasis, clarifying that targeting lncOSLMT has significant clinical translational value for targeted treatment of osteosarcoma lung metastases, especially in osteosarcoma liquid biopsy and early metastasis prediction, and is of great importance in ensuring adequate clinical safety.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

Construction method of prediction model of recurrence probability of specific disease

The invention discloses a method for constructing a prediction model for the recurrence probability of a specific disease, and the method comprises the steps: collecting the medical data of a patient with the specific disease and a personalized treatment scheme, carrying out the preprocessing of the medical data of the patient, carrying out the feature extraction of the medical data of the patient through a contrast ratio, and obtaining a baseline feature; performing time sequence analysis on the baseline characteristics by adopting a deviation value to obtain time sequence data, calculating a personalized risk index according to the time sequence data, performing influence analysis on the personalized treatment scheme according to the time sequence data to obtain a prognosis factor, performing risk stratification on the personalized risk index to obtain a level risk, and performing risk assessment on the level risk. And constructing a specific disease recurrence probability prediction model according to the prognosis factors and the level risk, optimizing the specific disease recurrence probability prediction model, and outputting a target model. The method not only can improve the construction precision of the recurrence probability prediction model, but also has good interpretability, and can be directly applied to a disease recurrence probability prediction system.
Owner:CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI

Biomarker for prognosis prediction of melanoma, application and model construction method

The invention discloses a combination of melanoma biomarkers found on the basis of transcriptomics data of lesion sites of melanoma and vitiligo. The biomarker combination is composed of two genes, namely BCAN and OCA2. The invention also discloses a method for extracting reverse expression gene characteristics based on transcriptomics data of melanoma and vitiligo lesion sites. Meanwhile, the invention also discloses application of a melanoma prognosis model constructed by using the group of markers in prognosis evaluation of melanoma patients and a model construction method. The risk scoring model can be used as an independent prognosis factor of melanoma patients, and proves that patients in a high-risk group are related to poor prognosis, and the prognosis prediction accuracy is good.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI